文献速递乳腺癌放疗

中度大分割放疗在乳腺癌患者中较常规分割放疗具有更有利的安全性特征:一项多中心前瞻性真实世界数据采集分析

Favorable safety profile of moderate hypofractionated over normofractionated radiotherapy in breast cancer patients: a multicentric prospective real-life data farming analysis.
PubMed 文献 · Radiat Oncol · 2022-04-20

该多中心前瞻性真实世界研究纳入2015年11月至2020年2月3个综合癌症中心的3518例乳腺癌患者,比较中度大分割全乳放疗(HFRT)与常规分割放疗(NFRT)的急性毒性。HFRT组急性2-3级皮炎、1-3级乳房水肿、1-2级色素沉着和疼痛的发生率均低于NFRT组。高BMI和大乳房是2-3级皮炎的危险因素,作者认为HFRT可能是更优选择。

要点

  • HFRT组急性2-3级皮炎发生率8.9%,低于NFRT组的35.1%(p<0.001)。
  • HFRT组疼痛发生率33.4%,低于NFRT组的53.7%(p<0.001)。
  • 高BMI和大乳房与2-3级皮炎风险升高相关,无论采用NFRT还是HFRT。

核心结论

  • 作者认为,即使对于高BMI或大乳房的患者,乳腺HFRT也可能是更好的选择。
  • 急性毒性为轻度至中度,且HFRT较NFRT更低。
  • 真实世界数据结果稳健,支持将HFRT应用于随机研究人群之外的患者。
  • 长期真实世界数据有待进一步研究。

研究设计与样本

  • 多中心前瞻性真实世界数据采集分析,纳入2015年11月至2020年2月3个综合癌症中心接受局部区域放疗的乳腺癌患者。
  • 通过系统性数据采集策略,前瞻性完成急性毒性评估表(CTCAEv4.0)并电子化提取,各中心结果匿名合并为单一数据库分析。
  • 采用卡方检验比较HFRT与NFRT,并在622例患者的亚研究中通过多因素logistic回归分析识别皮炎危险因素。

主要发现

  • 共分析3518例T0-4 N0-3、大部分M0(85.8%)的乳腺癌患者,中位年龄60.7岁(范围24-96岁)。
  • 急性2-3级皮炎发生率HFRT组8.9% vs NFRT组35.1%(卡方=373.7;p<0.001)。
  • 急性1-3级乳房水肿发生率HFRT组29.0% vs NFRT组37.0%(卡方=23.1;p<0.001)。
  • 急性1-2级色素沉着发生率HFRT组27.0% vs NFRT组55.8%(卡方=279.2;p<0.001)。
  • 疼痛发生率HFRT组33.4% vs NFRT组53.7%(卡方=137.1;p<0.001)。

关键数值与推荐

  • 多因素分析显示,高BMI与2-3级皮炎风险升高相关(OR=2.30,95%CI 1.28-4.26,p<0.01)。
  • 大乳房与2-3级皮炎风险升高相关(OR=1.88,95%CI 1.07-3.28,p<0.01)。
  • 乳房肿物切除较乳房切除术与2-3级皮炎风险相关(OR=0.52,95%CI 0.27-0.97,p<0.05),无论采用NFRT还是HFRT。

临床怎么用

  • 作者认为,乳腺HFRT可能是更好的选择,即使对于高BMI或大乳房的患者。
  • 真实世界数据支持将HFRT应用于随机研究人群之外的患者。
  • 长期真实世界数据有待进一步研究。

局限性

  • 长期真实世界数据有待进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Moderately hypofractionated whole-breast radiotherapy (HFRT) has proven to be as safe and efficient as normofractionated radiotherapy (NFRT) in randomized trials resulting in major changes in clinical practice. Toxicity rates observed in selected clinical trial patients may differ from those observed in unselected patients with possible comorbidities and frailty in real-life. This study aimed to examine the influence of HFRT versus NFRT on acute toxicity and identify risks factors of dermatitis in real-life patients. MATERIALS AND METHODS: Prospective data from breast cancer patients, treated with locoregional radiotherapy were collected between November 2015 and February 2020 in 3 comprehensive cancer centers. Through a systematic data-farming strategy, acute toxicity evaluation forms (CTCAEv4.0) were prospectively completed and extracted electronically. The results from each center were then anonymously merged into a single database for analysis. A Chi-2 test was used to compare HFRT and NFRT. Furthermore, risk factors of dermatitis were identified in a sub-study (622 patients) by multivariate logistic regression analysis. RESULTS: In total, 3518 T0-4 N0-3 mostly M0 (85.8%) breast cancer patients with a median age of 60.7 (24-96 years old) were analyzed. Acute grade 2-3 dermatitis, grade 1-3 breast oedema, and grade 1-2 hyperpigmentation were less frequent with HFRT versus NFRT: respectively 8.9% versus 35.1% (Chi-2 = 373.7; p < 0.001), 29.0% versus 37.0% (Chi-2 = 23.1; p < 0.001) and 27.0% versus 55.8% (Chi-2 = 279.2; p < 0.001). Fewer patients experienced pain with HFRT versus NFRT: 33.4% versus 53.7% respectively (Chi-2 = 137.1; p < 0.001). Factors such as high BMI (OR = 2.30 [95% CI, 1.28-4.26], p < 0.01), large breast size (OR = 1.88 [95% CI, 1.07-3.28], p < 0.01) and lumpectomy over mastectomy (OR = 0.52 [95% CI, 0.27-0.97], p < 0.05) were associated with greater risk factors of grade 2-3 dermatitis in multivariate analysis regardless of NFRT or HFRT. CONCLUSION: The results of this study suggests that breast HFRT may be a better option even for patients with a high BMI or large breast size. Acute toxicity was low to mild, and lower with HFRT compared to NFRT. Results from real-life data were robust, and support the use of HFRT beyond randomized study populations. Long-term real-life data awaits further investigation.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Issoufaly I, Petit C, Guihard S, et al. Favorable safety profile of moderate hypofractionated over normofractionated radiotherapy in breast cancer patients: a multicentric prospective real-life data farming analysis. Radiat Oncol. 2022. PMID: 35443729. doi:10.1186/s13014-022-02044-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。